α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of aggregates (Lewy bodies) in neurons. alpha-Synuclein is the major protein in Lewy bodies and rare mutations in alpha-synuclein cause early-onset PD. Consequently, alpha-synuclein is implicated in the pathogenesis of PD. Here, we have investigated the degradation pathways of alpha-synuclein, using a stable inducible PC12 cell model, where the expression of exogenous human wild-type, A30P, or A53T alpha-synuclein can be switched on and off. We have used a panel of inhibitors/stimulators of autophagy and proteasome function and followed alpha-synuclein degradation in these cells. We found that not only is alpha-synuclein degraded by the proteasome, but it is also degraded by autophagy. A role for autophagy was further supported by the presence of alpha-synuclein in organelles with the ultrastructural features of autophagic vesicles. Since rapamycin, a stimulator of autophagy, increased clearance of alpha-synuclein, it merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, mutant forms of synuclein and oligomers are dependent on the autophagy–lysosome pathway for their clearance4–6.”
From Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice (2018) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies suggest that α-synuclein is degraded by macroautophagy, chaperone-mediated autophagy, and the proteasome20–23.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Macroautophagy is a key pathway for the clearance of aggregate-prone cytosolic proteins.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
In the citing paper
“Early evidence suggested roles for CMA and macroautophagy in degrading SNCA/α‐synuclein (Webb et al, 2003; Cuervo et al, 2004).”
From Autophagy in major human diseases (2021) · cites this paper as Webb et al, 2003
In the citing paper
“We previously showed that EGFP-HDQ74 is cleared by autophagy.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Research works printed but not linked: 2
- Furlong, R. A., Narain, Y., Rankin, J., Wyttenbach, A., and Rubinsztein, D. C. (2000) Biochem. J. 346, 577-581 · DOI · Paper page
- Biederbick, A., Kern, H. F., and Elsasser, H. P. (1995) Eur. J. Cell Biol. 66, 3-14
Cited by
Items 801–900 of 1,001
Lee, K. I., Kim, M. J., Koh, H., Lee, J. I., Namkoong, S., Oh, W. K., & Park, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.145 · Cited by 38
Targeted Degradation of Alpha-Synuclein by Autophagosome-Anchoring Chimera Peptides
Tong, Y., Zhu, W., Chen, J., Zhang, W., Xu, F., & Pang, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01303 · Cited by 36
A transition to degeneration triggered by oxidative stress in degenerative disorders
Stern, M., & McNew, J. A. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00943-9 · Cited by 33
Padilla-Godínez, F. J., Ramos-Acevedo, R., Martínez-Becerril, H. A., Bernal-Conde, L. D., Garrido-Figueroa, J. F., Hiriart, M., Hernández-López, A., Argüero‐Sánchez, R., Callea, F., & Guerra‐Crespo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212467 · Cited by 34
Zhu, Z., Liu, L., Su, C.-F., Liu, J., Tong, B. C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Guan, X.-J., Kan, Y., et al. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00871-0 · Cited by 35
Combined chronic copper exposure and aging lead to neurotoxicity in vivo
González-Alcocer, A., Gopar‐Cuevas, Y., Soto‐Domínguez, A., Castillo-Velázquez, U., Loera‐Arias, M. D. J., Cárdenas, O. S., Montes‐de‐Oca‐Luna, R., García‐García, A., & Rodríguez‐Rocha, H. (2023) · NeuroToxicology · doi:10.1016/j.neuro.2023.02.002 · Cited by 35
Synphilin-1 isoforms in Parkinson’s disease: regulation by phosphorylation and ubiquitylation
Szargel, R., Rott, R., & Engelender, S. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7343-0 · Cited by 35
Yang, F. W., Yang, Y., Mao, C., Cao, B., Cai, Z.-L., Shi, J., Huang, J., Zhang, P., & Liu, C.-F. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.027 · Cited by 33
Phadwal, K., Kurian, D., Salamat, M. K. F., MacRae, V. E., Diack, A. B., & Manson, J. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-28296-y · Cited by 37
Mahogunin ring finger 1 suppresses misfolded polyglutamine aggregation and cytotoxicity
Chhangani, D., Nukina, N., Kurosawa, M., Amanullah, A., Joshi, V., Upadhyay, A., & Mishra, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.014 · Cited by 33
“synuclein, expanded polyglutamine proteins and mutant SOD1 proteins, and the loss of autophagy causes neurodegenerative disease in mice [2,21–24].”
BackgroundChen, K., Yuan, R., Geng, S., Zhang, Y., Ran, T., Kowalski, E., Liu, J., & Li, L. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.10.002 · Cited by 28
Autophagy and lysosomal pathways in nervous system disorders
Bingol, B. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.04.009 · Cited by 35
Yan, J., Huang, J., Liu, A., Wu, J., Fan, H., Shen, M., Lai, X., Ma, H., Sun, W., Yang, J., et al. (2020) · Aging · doi:10.18632/aging.202189 · Cited by 32
“Autophagy can promote the degradation of α-synuclein by the proteasome and autophagolysosomal pathways [10].”
BackgroundInfluentialTruncation or proteolysis of α-synuclein in Parkinsonism
Suthar, S. K., & Lee, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101978 · Cited by 36
Xiong, J., Xia, M., Xu, M., Zhang, Y., Abais, J. M., Li, G., Riebling, C. R., Ritter, J. K., Boini, K. M., & Li, P. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12173 · Cited by 36
“Transient changes in intracytosolic Ca, which were affected by blocking the IP3R-specific Ca 2+ oscillatory activity [42], might not result in decreased steady-state intracellular Ca levels but could impact the activity of calpain and autophagy regulated by the A”
BackgroundExposure to dibenzofuran triggers autophagy in lung cells
Duarte, F. V., Teodoro, J. S., Rolo, A. P., & Palmeira, C. M. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.11.029 · Cited by 32
Ryu, H.-W., Oh, W. K., Jang, I., & Park, J. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.053 · Cited by 34
Christensen, D. P., Ejlerskov, P., Rasmussen, I., & Vilhardt, F. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0519-5 · Cited by 36
“In PD and other malconformation brain diseases, where pathology is associated with abnormal protein folding and aggregate accumulation, autophagy is activated [16, 17] to compensate for the often compromised proteasomal function.”
BackgroundGuo, S., Gao, X., Gu, Y.-R., Wan, Z., Lu, A.-M., Qin, Z.-H., & Luo, L. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/4394261 · Cited by 37
Rivero-Ríos, P., Romo-Lozano, M., Fasiczka, R., Naaldijk, Y., & Hilfiker, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00556 · Cited by 31
Huang, Y. M., Chegini, F., Chua, G., Murphy, K., Gai, W.-P., & Halliday, G. M. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-2 · Cited by 33
“autophagic pathways [26-30].”
Perspectives of RAS and RHEB GTPase Signaling Pathways in Regenerating Brain Neurons
Schöneborn, H., Raudzus, F., Coppey, M., Neumann, S., & Heumann, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124052 · Cited by 33
Zhu, L., Sun, C., Ren, J., Wang, G., Ma, R., Sun, L., Yang, D., Gao, S., Ning, K., Wang, Z., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1313-y · Cited by 32
Ha, T.-Y., Choi, Y. R., Noh, H. R., Cha, S., Kim, J.-B., & Park, S. M. (2021) · Molecular Brain · doi:10.1186/s13041-021-00834-2 · Cited by 34
Autophagy in ageing and ageing-related neurodegenerative diseases
Karabiyik, C., Frake, R. A., Park, S. J., Tanasa, M. P., & Rubinsztein, D. C. (2021) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2021.05 · Cited by 36
Self-citationKim, K.-R., Cho, E., Eom, J.-W., Oh, S., Nakamura, T., Oh, C.-K., Lipton, S. A., & Kim, Y. H. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01004-0 · Cited by 33
LC3-II Tagging and Western Blotting for Monitoring Autophagic Activity in Mammalian Cells
Streeter, A., Menzies, F. M., & Rubinsztein, D. C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_8 · Cited by 35
Self-citationTargeted de-repression of neuronal Nrf2 inhibits α-synuclein accumulation
Baxter, P. S., Márkus, N. M., Dando, O., He, X., Al-Mubarak, B. R., Qiu, J., & Hardingham, G. E. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03507-z · Cited by 32
From sequence to function: using RNAi to elucidate mechanisms of human disease
Wolters, N. M., & MacKeigan, J. P. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402311 · Cited by 34
Biomedical Implications of Autophagy in Macromolecule Storage Disorders
Palhegyi, A. M., Seranova, E., Dimova, S., Hoque, S., & Sarkar, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00179 · Cited by 34
“Despite autophagy defects in PD, induction of autophagy could promote autophagic clearance of α-synuclein mutants (Webb et al., 2003), and has been shown to be beneficial in toxininduced or transgenic mouse models of PD. Genetic activation of autophagy in α-synuclein transgenic mice or rats by…”
BackgroundMiwa, H., Kubo, T., Suzuki, A., & Kondo, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.03.003 · Cited by 35
Les deux visages de l’autophagie dans le système nerveux
Puyal, J., Ginet, V., Vaslin, A., Truttmann, A. C., & Clarke, P. G. H. (2009) · médecine/sciences · doi:10.1051/medsci/2009254383 · Cited by 31
“En effet, des inhibiteurs d’autophagie, comme la 3-MA ou la bafilomycine A1, diminuent la dégradation des agrégats alors que des inducteurs d’autophagie comme la rapamycine augmentent leur élimination et diminuent ainsi leur toxicité [31, 32].”
BackgroundFričová, D., Harsányiová, J., & Trancikova, A. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228666 · Cited by 31
“Let-7 is another miRNA that presumably regulates α-Syn levels, through the formation of autophagosomes that lead to the failure of α-Syn lysosomal degradation [91,93].”
BackgroundAutophagy system as a potential therapeutic target for neurodegenerative diseases
Cui, M., Yoshimori, T., & Nakamura, S. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105308 · Cited by 29
Chung, L. Y.-R., Lin, Y., Liu, C., Tai, Y., Lin, H., Lin, C., & Chen, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.845930 · Cited by 35
CCPG1 recognizes endoplasmic reticulum luminal proteins for selective ER-phagy
Ishii, S., Chino, H., Ode, K. L., Kurikawa, Y., Ueda, H. R., Matsuura, A., Mizushima, N., & Itakura, E. (2023) · Molecular Biology of the Cell · doi:10.1091/mbc.e22-09-0432 · Cited by 35
“…structures, such as organelles (Lemasters, 2005; Singh et al. , 2009; Maejima et al. , 2013), ribosomes (Kraft et al. , 2008), protein aggregates (Webb et al. , 2003; Øverbye et al. , 2007), invading pathogens (Nakagawa et al. , 2004), lysosomes (Maejima et al. , 2013) and protein droplets…”
BackgroundPitcairn, C., Murata, N., Zalon, A. J., Stojkovska, I., & Mazzulli, J. R. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0610-22.2023 · Cited by 30
Taylor, J. M., Brody, K. M., & Lockhart, P. J. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.05.011 · Cited by 34
Validity of the MPTP-Treated Mouse as a Model for Parkinson’s Disease
Klemann, C. J. H. M., Martens, G. J. M., Poelmans, G., & Visser, J. E. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9103-8 · Cited by 31
Deriziotis, P., & Tabrizi, S. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.06.011 · Cited by 38
“polyQ and α-synuclein clearance in cell models [136], and has been”
BackgroundTowards an Understanding of the Anti-Aging Mechanism of Caloric Restriction
Cavallini, G., Donati, A., Gori, Z., & Bergamini, E. (2008) · Current Aging Science · doi:10.2174/1874609810801010004 · Cited by 32
Lysosomal Proteins as a Therapeutic Target in Neurodegeneration
Donald, J. M. M., & Krainc, D. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-050715-104432 · Cited by 31
Zhu, M., Zhang, S., Tian, X., & Wu, C. (2017) · Autophagy · doi:10.1080/15548627.2017.1362524 · Cited by 30
Cho, B., Kim, T., Huh, Y.-J., Lee, J., & Lee, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205208 · Cited by 31
“Rapamycin, an inhibitor of the mammalian target of rapamycin, consistently promotes degradation of wild-type and mutant α-synuclein [30] and rescues loss of DA neurons and parkinsonism in a 6-OHDA-induced PD mouse model [31].”
BackgroundEvidence Linking Protein Misfolding to Quality Control in Progressive Neurodegenerative Diseases
Kabir, M. T., Uddin, M. S., Abdeen, A., Ashraf, G. M., Perveen, A., Hafeez, A., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200618114924 · Cited by 29
An Update on Autophagy in Prion Diseases
López-Pérez, Ó., Badiola, J. J., Bolea, R., Ferrer, I., Llorens, F., & Martín‐Burriel, I. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00975 · Cited by 31
“Accumulation of PrPSc in the central nervous system (CNS), which is believed to be the main pathogenic event responsible for the pathological changes produced in TSE patients, induces spongiform degeneration, glial activation and neuronal loss (Wells and McGill, 1992; Wood et al., 1997).”
BackgroundTOLLIP acts as a cargo adaptor to promote lysosomal degradation of aberrant ER membrane proteins
Hayashi, Y., Takatori, S., Warsame, W. Y., Tomita, T., Fujisawa, T., & Ichijo, H. (2023) · EMBO Journal · doi:10.15252/embj.2023114272 · Cited by 27
“Since cytosolic A53T a -synuclein is efficiently degraded by lysosomes (Webb et al , 2003), we reasoned that A53T-HP behaves as an aberrant ER membrane protein with a cytosolic degron, facilitating its lysosomal degradation.”
Synaptic Protein Alterations in Parkinson’s Disease
Pienaar, I. S., Burn, D. J., Morris, C. M., & Dexter, D. T. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8226-9 · Cited by 32
Mishra, A. K., Mishra, S., Rajput, C., Rasheed, M. S. U., Patel, D. K., & Singh, M. P. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9800-3 · Cited by 29
A comprehensive screening of copy number variability in dementia with Lewy bodies
Kun‐Rodrigues, C., Orme, T., Carmona, S., Hernandez, D. G., Ross, O. A., Eicher, J. D., Shepherd, C. E., Parkkinen, L., Darwent, L., Heckman, M. G., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.019 · Cited by 28
“However, recent data have highlighted the importance of lysosomal pathways for degradation of this protein (Webb et al., 2003).”
BackgroundGenetic causes of PD: A pathway to disease modification
Toffoli, M., Vieira, S. R. L., & Schapira, A. H. V. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108022 · Cited by 29
“Studies have shown that rapamycin reduced A-SYN aggregation and associated neurodegeneration in PC12 cells expressing wild-type or mutant A-SYN (Webb et al., 2003), and in A-SYN-overexpressing rats (Decressac et al.”
BackgroundCurrent Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms
Wildburger, N. C., Hartke, A.-S., Schidlitzki, A., & Richter, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.598446 · Cited by 30
“…intracellular signaling and synchronization to deliver their cargo to the lysosome in an ATP-dependent manner (Schellens et al., 1988; Arias and Cuervo, 2011; Kaushik and Cuervo, 2012). aSyn degradation occurs through both mechanisms (Webb et al., 2003; Cuervo et al., 2004; Lee et al., 2004).”
BackgroundInfluentialHaddad, M. E., Eid, S., Harb, F., Massry, M. E., Azar, S. T., Sauleau, E., & Eid, A. A. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.02.011 · Cited by 30
Myotubularin-related phosphatase 5 is a critical determinant of autophagy in neurons
Chua, J. P., Bedi, K., Paulsen, M. T., Ljungman, M. E., Tank, E. M. H., Kim, E. S., McBride, J. P., Colon, J., Ward, M. E., Weisman, L. S., et al. (2022) · Current Biology · doi:10.1016/j.cub.2022.04.053 · Cited by 29
Duarte‐Silva, S., Neves‐Carvalho, A., Soares‐Cunha, C., Teixeira‐Castro, A., Oliveira, P., Silva‐Fernandes, A., & Maciel, P. (2014) · The Cerebellum · doi:10.1007/s12311-014-0589-9 · Cited by 30
“The accumulation of misfolded proteins in cells is a common feature in aging and in several neurodegenerative disorders [26], which makes autophagy a prominent target for the treatment of such diseases; these include amyotrophic lateral sclerosis (ALS), Parkinson disease (PD), AD, Huntington’s disease (HD), and Machad…”
BackgroundIshibashi, D., Homma, T., Nakagaki, T., Fuse, T., Sano, K., Takatsuki, H., Atarashi, R., & Nishida, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137958 · Cited by 31
Schommer, J., Marwarha, G., Schommer, T., Flick, T., Lund, J., & Ghribi, O. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0420-5 · Cited by 28
RetractedATG16 mediates the autophagic degradation of the 19S proteasomal subunits PSMD1 and PSMD2
Xiong, Q., Fischer, S., Karow, M. A., Müller, R., Meßling, S., & Eichinger, L. (2018) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2018.09.002 · Cited by 29
Yuan, N.-N., Cai, C.-Z., Wu, M.-Y., Zhu, Q., Su, H., Li, M., Ren, J., Tan, J., & Lu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00016 · Cited by 28
“α-syn can be degraded by both autophagy and ubiquitinproteasome system (UPS) (Webb et al., 2003).”
BackgroundWen, R. H., Stanar, P., Tam, B., & Moritz, O. L. (2019) · Autophagy · doi:10.1080/15548627.2019.1596487 · Cited by 27
Cell Clearing Systems Bridging Neuro-Immunity and Synaptic Plasticity
Limanaqi, F., Biagioni, F., Busceti, C. L., Ryskalin, L., Soldani, P., Frati, A., & Fornai, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092197 · Cited by 29
Hafycz, J. M., & Naidoo, N. N. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00140 · Cited by 32
Sheng, J., Olrichs, N. K., Gadella, B. M., Kaloyanova, D. V., & Helms, J. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186530 · Cited by 31
PC12 Cells as a model for parkinson's disease research
Malagelada, C., & Greene, L. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00029-4 · Cited by 45
Autophagy contributes to degradation of Hirano bodies
Kim, D.-H., Davis, R. C., Furukawa, R., & Fechheimer, M. (2009) · Autophagy · doi:10.4161/auto.5.1.7228 · Cited by 27
Leucine‐rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease
Cogo, S., Manzoni, C., Lewis, P. A., & Greggio, E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14908 · Cited by 27
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
Fouka, M., Mavroeidi, P., Tsaka, G., & Xilouri, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.559791 · Cited by 29
“…direction, rapamycin, an inhibitor of mTOR, was shown to reduce αsynuclein accumulation in WT, A30P and A53T α-synucleinoverexpressing PC12 cells (Webb et al., 2003), to attenuate dopaminergic degeneration in neurotoxin-induced (Dehay et al., 2010; Malagelada et al., 2010; Liu et al., 2013)…”
BackgroundNovel autophagy inducers by accelerating lysosomal clustering against Parkinson’s disease
Date, Y., Sasazawa, Y., Kitagawa, M., Gejima, K., Suzuki, A., Saya, H., Kida, Y. S., Imoto, M., Itakura, E., Hattori, N., et al. (2024) · eLife · doi:10.7554/elife.98649 · Cited by 32
“Research interest is increasing in the induction of autophagy, a primary protein degradation system that removes Syn aggregates, using small-molecule compounds as a therapeutic approach (Webb et al., 2003; Gao et al., 2019; Choi et al., 2020a).”
Ras and Rheb Signaling in Survival and Cell Death
Ehrkamp, A., Herrmann, C., Stoll, R., & Heumann, R. (2013) · Cancers · doi:10.3390/cancers5020639 · Cited by 32
“cytoplasmic accumulation of insoluble aggregates [122–124].”
Non-repair Pathways for Minimizing Protein Isoaspartyl Damage in the Yeast Saccharomyces cerevisiae
Patananan, A. N., Capri, J. R., Whitelegge, J. P., & Clarke, S. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564385 · Cited by 30
“Conversely, the autophagy pathway largely degrades long lived proteins (61, 62) and protein aggregates (63, 64).”
BackgroundPaine, S., Anderson, G. W., Bedford, K., Lawler, K., Mayer, R. J., Lowe, J. S., & Bedford, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054711 · Cited by 30
Feleciano, D. R., Juenemann, K., Iburg, M., Brás, I. C., Holmberg, C. I., & Kirstein, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00009 · Cited by 31
“The autophagy pathway has been shown to eliminate disease-associated proteins such as Aβ, α-synuclein or mHtt (Ravikumar et al., 2002; Webb et al., 2003; Yu et al., 2004).”
BackgroundParkinson’s Disease and Autophagy
Sánchez-Pérez, A. M., Clausell, B. C., Sanchez‐Andrés, J. V., & Herrero, M. T. (2012) · Parkinson s Disease · doi:10.1155/2012/429524 · Cited by 29
“Confirming these findings, it has been shown that inhibition of macroautophagy has much smaller effects (if any effect at all) on the clearance of wild-type α-synuclein than on the clearance of the mutant aggregate-prone species [27].”
BackgroundInfluentialAutophagy and Cell Death in Caenorhabditis elegans
Tavernarakis, N., & Samara, C. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208783378770 · Cited by 31
“Although proteasomes and CMA degrade soluble forms of -synuclein, insoluble toxic forms and aggregates are cleared by macro-autophagy [205, 206].”
BackgroundBrain metabolism as a modulator of autophagy in neurodegeneration
Lim, Y., Cho, H., & Kim, E. K. (2016) · Brain Research · doi:10.1016/j.brainres.2016.02.049 · Cited by 29
Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes
Chen, L.-L., Wu, J.-C., Wang, L.-H., Wang, J., Qin, Z.-H., Difiglia, M., & Lin, F. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.162 · Cited by 26
What lysosomes actually tell us about Parkinson’s disease?
Bourdenx, M., & Dehay, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.008 · Cited by 26
A sensitive assay reveals structural requirements for α-synuclein fibril growth
Dhavale, D. D., Tsai, C., Bagchi, D. P., Engel, L. A., Sarezky, J., & Kotzbauer, P. T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767053 · Cited by 26
Marrero-Winkens, C., Sankaran, C., & Schätzl, H. M. (2020) · Biomolecules · doi:10.3390/biom10091305 · Cited by 30
“An enhanced clearance of α-syn following the induction of autophagy has also been reported for cultured cells expressing wild-type or mutant α-syn [101,102].”
BackgroundAutophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions
Martins, W. K., Silva, M. N., Pandey, K. R., Maejima, I., Ramalho, E. D. S., Olivon, V. C., Diniz, S. N., & Grasso, D. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100033 · Cited by 31
Γεωργίου, Μ., Yang, C., Atkinson, R., Pan, K., Buskin, A., Molina, M. M., Collin, J., Al-Aama, J. Y., Görtler, F., Ludwig, S. E. J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.759 · Cited by 27
Person‐specific differences in ubiquitin‐proteasome mediated proteostasis in human neurons
Hsieh, Y., Augur, Z. M., Arbery, M. R., Ashour, N., Barrett, K., Pearse, R. V., Tio, E. S., Duong, D. M., Felsky, D., Jager, P. L. D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13680 · Cited by 29
“6,7 Therefore, the accumulation of abnormal protein aggregates, including excessively phosphorylated microtubule-associated protein tau (p-tau) 8–10 and α -synuclein, 11,12 is likely mediated at least in part by the UPS.”
BackgroundThe interplay between probiotics and host autophagy: mechanisms of action and emerging insights
Sadeghloo, Z., Nabavi-Rad, A., Zali, M. R., Klionsky, D. J., & Yadegar, A. (2024) · Autophagy · doi:10.1080/15548627.2024.2403277 · Cited by 31
“Autophagy is responsible for the cytoplasmic clearance of SNCA observed in PD [155].”
Modeling proteasome dynamics in Parkinson's disease
Sneppen, K., Lizana, L., Jensen, M. H., Pigolotti, S., & Otzen, D. E. (2009) · Physical Biology · doi:10.1088/1478-3975/6/3/036005 · Cited by 27
Ouzounoglou, E., Kalamatianos, D., Emmanouilidou, E., Xilouri, M., Stefanis, L., Vekrellis, K., & Manolakos, E. S. (2014) · BMC Systems Biology · doi:10.1186/1752-0509-8-54 · Cited by 26
“As for the contribution of other proteolytic machineries in the degradation of ASYN, there is significant evidence that both macroautophagy [16] and the proteasome [18-20] contribute to the removal of various ASYN species (from monomers to oligomers).”
BackgroundAutophagy protects against de novo formation of the [PSI+] prion in yeast
Speldewinde, S. H., Doronina, V. A., & Grant, C. M. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-08-0548 · Cited by 27
“…autophagy plays a role in the clearance of misfolded proteins (Hara et al., 2006; Komatsu et al., 2006), and amyloidogenic aggregates such as those formed by α-synuclein and huntingtin have been identified as substrates of autophagy (Webb et al., 2003; Ravikumar et al., 2004; Iwata et al., 2005).”
BackgroundPrelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds
Madsen, H. B., & Vilhardt, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010227 · Cited by 28
“Several studies have shown that pathological forms of α-synuclein [117,142,196,197,199], huntingtin [142,200–202], and tau [203–206] are substrates of the chaperone-mediated and the macro-autophagosomal pathways.”
BackgroundLatina, V., Caioli, S., Zona, C., Ciotti, M. T., Borreca, A., Calissano, P., & Amadoro, G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00487 · Cited by 26
“…participating in synaptic vesicle exocytosis, endocytosis, and recycling- are known to be ubiquitinated and UPS substrates (Bennett et al., 1999; Webb et al., 2003; Segref and Hoppe, 2009; Bingol and Sheng, 2011; Franco et al., 2011; Na et al., 2012; Hakim et al., 2016) and UPS components are…”
BackgroundXu, Y., Zhi, F., Mao, J., Peng, Y., Shao, N., Balboni, G., Yang, Y., & Xia, Y. (2020) · Aging · doi:10.18632/aging.103970 · Cited by 32
Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology
Liu, X., Balaraman, K., Lynch, C. C., Hebron, M. L., Wolf, C., & Moussa, C. (2021) · Metabolites · doi:10.3390/metabo11090622 · Cited by 27
Ha, J., Kim, J., Kim, S.-E., & Son, J. H. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2013.12.064 · Cited by 26
Church, T. R., & Margolis, S. S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1531797 · Cited by 27
Chaperones and Proteostasis: Role in Parkinson’s Disease
Joshi, N., Raveendran, A., & Nagotu, S. (2020) · Diseases · doi:10.3390/diseases8020024 · Cited by 25
Progresses in both basic research and clinical trials of NAD+ in Parkinson’s disease
Maria Jose Perez, J., Baden, P., & Deleidi, M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111499 · Cited by 27
Potential Tear Biomarkers for the Diagnosis of Parkinson’s Disease—A Pilot Study
Acera, A., Gómez‐Esteban, J. C., Murueta‐Goyena, A., Galdós, M., Azkargorta, M., Elortza, F., Ruzafa, N., Ibarrondo, O., Pereiro, X., & Vecino, E. (2022) · Proteomes · doi:10.3390/proteomes10010004 · Cited by 26
“The ubiquitin proteasome (UPP) pathway has been proposed to play a key role in the degradation of α-syn [43]; however, there is growing evidence that the lysosome may also mediate the degradation of α-syn [44,45].”
BackgroundA New Zebrafish Model to Measure Neuronal α-Synuclein Clearance In Vivo
López, A., Gorb, A., Palha, N., Fleming, A., & Rubinsztein, D. C. (2022) · Genes · doi:10.3390/genes13050868 · Cited by 28
“Multiple cellular protein degradation systems can clear α-SYN, such as macro-autophagy, chaperone-mediated autophagy (CMA) and the proteasome [14,15].”
BackgroundSelf-citationZhu, H., Byrnes, C., Lee, Y. T., Tuymetova, G., Duffy, H. B. D., Bakir, J. Y., Pettit, S. N., Angina, J., Springer, D., Allende, M. L., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202300149r · Cited by 26
Han, S.-W., Kim, T.-Y., Bae, J.-S., Choi, J., & Ryu, K. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.05.070 · Cited by 27
Lewis, K. A., Yaeger, A., Demartino, G., & Thomas, P. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9258-y · Cited by 26
“However, the physiological clearance pathway(s) is controversial, since autophagy via the lysosome, the ubiquitin-proteasome system (UPS), and calciumdependent proteases all degrade αSyn (Bennett et al. 1999; Webb et al. 2003).”
BackgroundYeung, P. K. K., Lai, A. K. W., Son, H. J., Zhang, X., Hwang, O., Chung, S. S. M., & Chung, S. K. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.008 · Cited by 29
Metadata
- Authors
- Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C.
- Affiliations
- Addenbrooke's Hospital (GB)
- University of Cambridge (GB)
- Corresponding author
- Rubinsztein, David C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 27
- Pages
- 25009-25013
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2157535220
- Cited by
- 1,429
- References
- 37
- Citations by year
- 2026: 36 · 2025: 41 · 2024: 76 · 2023: 50 · 2022: 68 · 2021: 71 · 2020: 83 · 2019: 85 · 2018: 77 · 2017: 62 · 2016: 65 · 2015: 65 · 2014: 75 · 2013: 79 · 2012: 95
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6305 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Parkinson's UK
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- alpha-synuclein, Parkinson's disease, autophagy, proteasome, protein degradation, Lewy bodies, A30P mutation, A53T mutation, PC12 cells, rapamycin, autophagic vesicles, dopaminergic neurons
- MeSH terms
- Animals, Antibiotics, Antineoplastic, Autophagy, Cysteine Endopeptidases, Humans, Multienzyme Complexes, Nerve Tissue Proteins, PC12 Cells, Sirolimus, Proteasome Endopeptidase Complex, Rats, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.